Premier Perspectives The blog for insider insights in clinical development Medical and Regulatory Affairs Curves Ahead: What Brexit Means for Drug Development in the UK By Colin Hayward August 30, 2018 Featured Posts Medical and Regulatory Affairs The Regulatory Landscape for Immuno-gene Therapeutics in Hematological Malignances By Colin Hayward March 15, 2018 Consulting Brexit: Bust or Boon for the Clinical Trials Industry? By Colin Hayward July 21, 2017 Recent Posts By expertise area All expertise areas Medical DeviceRare DiseaseOncology & HematologyDiagnosticsDigital TherapeuticsMedTechPediatricsNeuroscienceAnalgesiaDermatologyOtherCOVID-19Cell & Gene TherapyWomen's HealthReal-World & Late PhaseCareers By functional area All functional areas Clinical Research: Phase 1 - Phase 4ConsultingData Management & BiostatisticsFunctional Service Provider (FSP)Global ComplianceMedical and Regulatory AffairsPatient and Stakeholder EngagementProject ManagementQualityReal-World Science and Late PhaseSafety/PharmacovigilanceStudy DesignStudy Start-UpOtherCOVID-19Product Development Tales from the Road – OBN Awards and ESMO Congress By Colin Hayward October 21, 2016 × ALSO OF INTERESTChief Medical Officer Discussing...Premier Research Sponsors, Presents at OCT...Premier Voices #1: Rare Oncology w/ Colin...
